mRNA or ChAd0x1 COVID-19 Vaccination of Adolescents Induces Robust Antibody and Cellular Responses With Continued Recognition of Omicron Following mRNA-1273.
mRNA or ChAd0x1 COVID-19 Vaccination of Adolescents Induces Robust Antibody and Cellular Responses With Continued Recognition of Omicron Following mRNA-1273.
复制标题
DOI：
10.3389/fimmu.2022.882515
复制
发表时间：
2022
影响因子：
7.3
通讯作者：
中科院分区：
文献类型：
--
作者：
儿童和青少年通常会患上轻度COVID-19。然而，那些有潜在身体健康问题的人患严重疾病的风险明显增加。在这里，我们全面分析了接受ChAdOx1 （n=6）或mRNA疫苗（mRNA-1273, n=8, BNT162b2, n=1）接种COVID-19疫苗的严重神经功能障碍青少年的抗体和细胞反应。接种后观察到强烈的免疫反应，两次剂量后抗体水平和中和效价均较高。在mRNA疫苗接种后，这两项指标也更高，并且在先前的自然感染中进一步增强，其中一次疫苗剂量足以产生峰值抗体反应。双重疫苗接种后产生了强大的t细胞应答，mRNA疫苗接种后也产生了更高的t细胞应答。早期t细胞的特征是显性效应记忆CD4+ t细胞群，具有1型细胞因子特征，并产生额外的IL-10。抗体水平在接种疫苗后至少维持了3个月，4名供者中有3名显示出可测量的抗欧米克隆变异的中和效价。t细胞的反应也保持强劲，产生了一个中央/干细胞记忆池，并对Omicron spike表现出强烈的反应性。这些数据表明，COVID-19疫苗在青少年中表现出很强的免疫原性，与自然感染后相比，两次接种或先前感染后单次接种可产生更高的免疫反应，并产生针对Omicron的活性。初步证据表明，mRNA疫苗接种比腺病毒递送引起更强的免疫反应，尽管后者也高于成人人群。因此，COVID-19疫苗在高危青少年中具有高度免疫原性，双重疫苗接种可能能够提供相对保护，抵御目前在全球占主导地位的欧米克隆变异。
Children and adolescents generally experience mild COVID-19. However, those with underlying physical health conditions are at a significantly increased risk of severe disease. Here, we present a comprehensive analysis of antibody and cellular responses in adolescents with severe neuro-disabilities who received COVID-19 vaccination with either ChAdOx1 (n=6) or an mRNA vaccine (mRNA-1273, n=8, BNT162b2, n=1). Strong immune responses were observed after vaccination and antibody levels and neutralisation titres were both higher after two doses. Both measures were also higher after mRNA vaccination and were further enhanced by prior natural infection where one vaccine dose was sufficient to generate peak antibody response. Robust T-cell responses were generated after dual vaccination and were also higher following mRNA vaccination. Early T-cells were characterised by a dominant effector-memory CD4+ T-cell population with a type-1 cytokine signature with additional production of IL-10. Antibody levels were well-maintained for at least 3 months after vaccination and 3 of 4 donors showed measurable neutralisation titres against the Omicron variant. T-cell responses also remained robust, with generation of a central/stem cell memory pool and showed strong reactivity against Omicron spike. These data demonstrate that COVID-19 vaccines display strong immunogenicity in adolescents and that dual vaccination, or single vaccination following prior infection, generate higher immune responses than seen after natural infection and develop activity against Omicron. Initial evidence suggests that mRNA vaccination elicits stronger immune responses than adenoviral delivery, although the latter is also higher than seen in adult populations. COVID-19 vaccines are therefore highly immunogenic in high-risk adolescents and dual vaccination might be able to provide relative protection against the Omicron variant that is currently globally dominant.
登录
查看更多内容
影响因子：
64.5
作者：
Payne RP;Longet S;Austin JA;Skelly DT;Dejnirattisai W;Adele S;Meardon N;Faustini S;Al-Taei S;Moore SC;Tipton T;Hering LM;Angyal A;Brown R;Nicols AR;Gillson N;Dobson SL;Amini A;Supasa P;Cross A;Bridges-Webb A;Reyes LS;Linder A;Sandhar G;Kilby JA;Tyerman JK;Altmann T;Hornsby H;Whitham R;Phillips E;Malone T;Hargreaves A;Shields A;Saei A;Foulkes S;Stafford L;Johnson S;Wootton DG;Conlon CP;Jeffery K;Matthews PC;Frater J;Deeks AS;Pollard AJ;Brown A;Rowland-Jones SL;Mongkolsapaya J;Barnes E;Hopkins S;Hall V;Dold C;Duncan CJA;Richter A;Carroll M;Screaton G;de Silva TI;Turtle L;Klenerman P;Dunachie S;PITCH Consortium
通讯作者：
PITCH Consortium
BNT162B2疫苗针对青少年关键COVID-19的有效性。
DOI：
10.1056/nejmoa2117995
发表时间：
2022-02-24
期刊：
The New England journal of medicine
影响因子：
--
作者：
Olson SM;Newhams MM;Halasa NB;Price AM;Boom JA;Sahni LC;Pannaraj PS;Irby K;Walker TC;Schwartz SP;Maddux AB;Mack EH;Bradford TT;Schuster JE;Nofziger RA;Cameron MA;Chiotos K;Cullimore ML;Gertz SJ;Levy ER;Kong M;Cvijanovich NZ;Staat MA;Kamidani S;Chatani BM;Bhumbra SS;Bline KE;Gaspers MG;Hobbs CV;Heidemann SM;Maamari M;Flori HR;Hume JR;Zinter MS;Michelson KN;Zambrano LD;Campbell AP;Patel MM;Randolph AG;Overcoming Covid-19 Investigators
通讯作者：
Overcoming Covid-19 Investigators
影响因子：
9.8
作者：
Rihn SJ;Merits A;Bakshi S;Turnbull ML;Wickenhagen A;Alexander AJT;Baillie C;Brennan B;Brown F;Brunker K;Bryden SR;Burness KA;Carmichael S;Cole SJ;Cowton VM;Davies P;Davis C;De Lorenzo G;Donald CL;Dorward M;Dunlop JI;Elliott M;Fares M;da Silva Filipe A;Freitas JR;Furnon W;Gestuveo RJ;Geyer A;Giesel D;Goldfarb DM;Goodman N;Gunson R;Hastie CJ;Herder V;Hughes J;Johnson C;Johnson N;Kohl A;Kerr K;Leech H;Lello LS;Li K;Lieber G;Liu X;Lingala R;Loney C;Mair D;McElwee MJ;McFarlane S;Nichols J;Nomikou K;Orr A;Orton RJ;Palmarini M;Parr YA;Pinto RM;Raggett S;Reid E;Robertson DL;Royle J;Cameron-Ruiz N;Shepherd JG;Smollett K;Stewart DG;Stewart M;Sugrue E;Szemiel AM;Taggart A;Thomson EC;Tong L;Torrie LS;Toth R;Varjak M;Wang S;Wilkinson SG;Wyatt PG;Zusinaite E;Alessi DR;Patel AH;Zaid A;Wilson SJ;Mahalingam S
通讯作者：
Mahalingam S
两剂SARS-COV-2疫苗接种会引起对新兴SARS-COV-2的鲁棒反应。
影响因子：
16.6
作者：
Skelly DT;Harding AC;Gilbert-Jaramillo J;Knight ML;Longet S;Brown A;Adele S;Adland E;Brown H;Medawar Laboratory Team;Tipton T;Stafford L;Mentzer AJ;Johnson SA;Amini A;OPTIC (Oxford Protective T cell Immunology for COVID-19) Clinical Group;Tan TK;Schimanski L;Huang KA;Rijal P;PITCH (Protective Immunity T cells in Health Care Worker) Study Group;C-MORE/PHOSP-C Group;Frater J;Goulder P;Conlon CP;Jeffery K;Dold C;Pollard AJ;Sigal A;de Oliveira T;Townsend AR;Klenerman P;Dunachie SJ;Barnes E;Carroll MW;James WS
通讯作者：
James WS
DOI：
10.1016/s0140-6736(21)02183-8
发表时间：
2021-10-16
期刊：
Lancet (London, England)
影响因子：
--
作者：
Tartof SY;Slezak JM;Fischer H;Hong V;Ackerson BK;Ranasinghe ON;Frankland TB;Ogun OA;Zamparo JM;Gray S;Valluri SR;Pan K;Angulo FJ;Jodar L;McLaughlin JM
通讯作者：
McLaughlin JM